Search

Your search keyword '"Fina, Mariapaola"' showing total 29 results
Start Over Author "Fina, Mariapaola"
29 results on '"Fina, Mariapaola"'

2. Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a phase II non-randomised trial (FLUMIZ)

Author

Zinzani, Pier Luigi, Tani, Monica, Pulsoni, Alessandro, Gobbi, Marco, Perotti, Alessio, De Luca, Stefano, Fabbri, Alberto, Zaccaria, Alfonso, Voso, Maria Teresa, Fattori, Pierpaolo, Guardigni, Luciano, Ronconi, Sonia, Cabras, Maria Giuseppina, Rigacci, Luigi, De Renzo, Amalia, Marchi, Enrica, Stefoni, Vittorio, Fina, Mariapaola, Pellegrini, Cinzia, Musuraca, Gerardo, Derenzini, Enrico, Pileri, Stefano, Fanti, Stefano, Piccaluga, Pier Paolo, and Baccarani, Michele

Published
2008
Full Text
View/download PDF

6. Role of [18F]Fluorodeoxyglucose Positron Emission Tomography Scan in the Follow-Up of Lymphoma

Author

ZINZANI, PIER LUIGI, STEFONI, VITTORIO, TANI, MONICA, FANTI, STEFANO, MUSURACA, GERARDO, CASTELLUCCI, PAOLO, FINA, MARIAPAOLA, AMBROSINI, VALENTINA, ALINARI, LAPO, DERENZINI, ENRICO, BACCI, FRANCESCO, PILERI, STEFANO, BACCARANI, MICHELE, Marchi E., Pellegrini C., Montini G., BROCCOLI, ALESSANDRO, Zinzani P.L., Stefoni V., Tani M., Fanti S., Musuraca G., Castellucci P., Marchi E., Fina M., Ambrosini V., Pellegrini C., Alinari L., Derenzini E., Montini G., Broccoli A., Bacci F., Pileri S., and Baccarani M.

Published
2009

7. A phase 1/2 study of lenalidomide and bendamustine (LEBEN) in chemorefractory Hodgkin lymphoma.

Author

Corazzelli, Gaetano, primary, Saggese, Mariangela, additional, Pavone, Vincenzo, additional, Angrilli, Francesco, additional, Zinzani, Pier Luigi, additional, Spina, Michele, additional, Fina, Mariapaola, additional, Crisci, Stefania, additional, Calemma, Rosa, additional, Arcamone, Manuela, additional, Morelli, Emanuela, additional, Galati, Domenico, additional, Frigeri, Ferdinando, additional, De Filippi, Rosaria, additional, and Pinto, Antonello, additional

Published
2014
Full Text
View/download PDF

8. Phase II Trial of Short-Course R-Chop Followed by 90Y-Ibritumomab Tiuxetan in Previously Untreated High-Risk Elderly Diffuse Large B-Cell Lymphoma Patients

Author

Zinzani, Pier Luigi, primary, Rossi, Giuseppe, additional, Franceschetti, Silvia, additional, Botto, Barbara, additional, Di Rocco, Alice, additional, Cabras, Maria Giuseppina, additional, Petti, Maria Concetta, additional, Stefoni, Vittorio, additional, Broccoli, Alessandro, additional, Fanti, Stefano, additional, Pellegrini, Cinzia, additional, Montini, Gian Carlo, additional, Gandolfi, Letizia, additional, Derenzini, Enrico, additional, Argnani, Lisa, additional, Fina, Mariapaola, additional, Tucci, Alessandra, additional, Bottelli, Chiara, additional, Pileri, Stefano, additional, and Baccarani, Michele, additional

Published
2010
Full Text
View/download PDF

9. A Phase II Trial of Rituximab-CHOP Chemotherapy Followed by Yttrium 90 (90Y) Ibritumomab Tiuxetan (90Y-IT) for Previously Untreated Elderly Diffuse Large B-Cell Lymphoma (DLBCL) Patients.

Author

Zinzani, Pier Luigi, primary, Fina, Mariapaola, additional, Tani, Monica, additional, Stefoni, Vittorio, additional, Gandolfi, Letizia, additional, Broccoli, Alessandro, additional, Pellegrini, Cinzia, additional, Derenzini, Enrico, additional, Rossi, Giuseppe, additional, Angelucci, Emanuele, additional, Gaidano, Gianluca, additional, Petti, Maria Concetta, additional, Martelli, Maurizio, additional, Vitolo, Umberto, additional, Fanti, Stefano, additional, and Baccarani, Michele, additional

Published
2009
Full Text
View/download PDF

10. Predictive role of Early Interim FDG-PET in Hodgkin Lymphoma.

Author

Stefoni, Vittorio, primary, Broccoli, Alessandro, additional, Alinari, Lapo, additional, Ambrosini, Valentina, additional, Derenzini, Enrico, additional, Fanti, Stefano, additional, Fina, Mariapaola, additional, Gandolfi, Letizia, additional, Marchi, Enrica, additional, Pellegrini, Cinzia, additional, Quirini, Federica, additional, Zinzani, Pier Luigi, additional, and Baccarani, Michele, additional

Published
2009
Full Text
View/download PDF

11. A Phase II Trial of R-FM (Rituximab, Fludarabine and Mitoxantrone) Chemotherapy Followed by Yttrium 90 (90Y) Ibritumomab Tiuxetan (90Y-IT) for Untreated Follicular Lymphoma (FL) Patients.

Author

Zinzani, Pier Luigi, primary, Tani, Monica, additional, Broccoli, Alessandro, additional, Derenzini, Enrico, additional, Pulsoni, Alessandro, additional, De Renzo, Amalia, additional, Fanti, Stefano, additional, Fina, Mariapaola, additional, Gandolfi, Letizia, additional, Pellegrini, Cinzia, additional, Stefoni, Vittorio, additional, and Baccarani, Michele, additional

Published
2009
Full Text
View/download PDF

12. Role of [18F]Fluorodeoxyglucose Positron Emission Tomography Scan in the Follow-Up of Lymphoma

Author

Luigi Zinzani, Pier, primary, Stefoni, Vittorio, additional, Tani, Monica, additional, Fanti, Stefano, additional, Musuraca, Gerardo, additional, Castellucci, Paolo, additional, Marchi, Enrica, additional, Fina, Mariapaola, additional, Ambrosini, Valentina, additional, Pellegrini, Cinzia, additional, Alinari, Lapo, additional, Derenzini, Enrico, additional, Montini, Giancarlo, additional, Broccoli, Alessandro, additional, Bacci, Francesco, additional, Pileri, Stefano, additional, and Baccarani, Michele, additional

Published
2009
Full Text
View/download PDF

14. Phase II Trial of Proteasome Inhibitor Bortezomib in Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma

Author

Zinzani, Pier Luigi, primary, Musuraca, Gerardo, additional, Tani, Monica, additional, Stefoni, Vittorio, additional, Marchi, Enrica, additional, Fina, Mariapaola, additional, Pellegrini, Cinzia, additional, Alinari, Lapo, additional, Derenzini, Enrico, additional, de Vivo, Antonio, additional, Sabattini, Elena, additional, Pileri, Stefano, additional, and Baccarani, Michele, additional

Published
2007
Full Text
View/download PDF

15. Predictive Role of Positron Emission Tomography in the Outcome of Patients with Follicular Lymphoma

Author

Zinzani, Pier Luigi, primary, Musuraca, Gerardo, additional, Alinari, Lapo, additional, Fanti, Stefano, additional, Tani, Monica, additional, Stefoni, Vittorio, additional, Marchi, Enrica, additional, Fina, Mariapaola, additional, Pellegrini, Cinzia, additional, Castellucci, Paolo, additional, Farsad, Mohsen, additional, and Baccarani, Michele, additional

Published
2007
Full Text
View/download PDF

16. VNCOP-B plus rituximab in the treatment of diffuse large B-cell lymphoma in the elderly

Author

Fina, Mariapaola, primary, Tani, Monica, additional, Stefoni, Vittorio, additional, Musuraca, Gerardo, additional, Marchi, Enrica, additional, Pellegrini, Cinzia, additional, Alinari, Lapo, additional, Derenzini, Enrico, additional, Bacci, Francesco, additional, Pileri, Stefano, additional, Baccarani, Michele, additional, and Zinzani, Pier Luigi, additional

Published
2007
Full Text
View/download PDF

17. A Phase II Trial of CHOP Chemotherapy Followed by Yttrium 90 (90Y) Ibritumomab Tiuxetan (Zevalin®) for Previously Untreated Elderly Diffuse Large B-Cell Lymphoma (DLBCL) Patients.

Author

Zinzani, Pier Luigi, primary, Tani, Monica, additional, Fanti, Stefano, additional, Stefoni, Vittorio, additional, Musuraca, Gerardo, additional, Castellucci, Paolo, additional, Marchi, Enrica, additional, Fina, Mariapaola, additional, and Baccarani, Michele, additional

Published
2006
Full Text
View/download PDF

19. A Phase II Trial of FM (Fludarabine and Mitoxantrone) Chemotherapy Followed by Yttrium 90 (90Y) Ibritumomab Tiuxetan (Zevalin®) for Previously Untreated Indolent Non-Follicular Lymphoma Patients.

Author

Zinzani, Pier Luigi, primary, Tani, Monica, additional, Fanti, Stefano, additional, Musuraca, Gerardo, additional, Perrotti, Alessio, additional, Vitolo, Umberto, additional, Fina, Mariapaola, additional, Botto, Barbara, additional, Marchi, Enrica, additional, Benevolo, Giulia, additional, Stefoni, Vittorio, additional, and Baccarani, Michele, additional

Published
2006
Full Text
View/download PDF

26. Role of [18F]fluorodeoxyglucose positron emission tomography scan in the follow-up of lymphoma.

Author

Zinzani PL, Stefoni V, Tani M, Fanti S, Musuraca G, Castellucci P, Marchi E, Fina M, Ambrosini V, Pellegrini C, Alinari L, Derenzini E, Montini G, Broccoli A, Bacci F, Pileri S, and Baccarani M

Subjects
Fluorodeoxyglucose F18, Follow-Up Studies, Humans, Lymphoma diagnosis, Lymphoma pathology, Prospective Studies, Radiopharmaceuticals, Recurrence, Lymphoma diagnostic imaging, Positron-Emission Tomography
Abstract

Purpose: In lymphoma, [(18)F]fluorodeoxyglucose positron emission tomography (FDG-PET) is routinely used for initial staging, early evaluation of treatment response, and identification of disease relapse. However, there are no prospective studies investigating the value of serial FDG-PET over time in patients in complete remission., Patients and Methods: All patients with lymphoma who achieved the first complete remission were prospectively enrolled onto the study and scheduled for serial FDG-PET scans at 6, 12, 18, and 24 months; further scans were then carried out on an annual basis. Overall, the population included 421 patients (160 patients with Hodgkin's lymphoma [HL], 183 patients with aggressive non-Hodgkin's lymphoma [NHL], and 78 patients with indolent follicular NHL). All patients had a regular follow-up evaluation, including complete clinical and laboratory evaluation, and final assessment of any suspect FDG-PET findings using other imaging procedures (computed tomography [CT] scan) and/or biopsy and/or clinical evolution. FDG-PET findings were reported as positive for relapse, inconclusive (when equivocal), or negative for relapse., Results: PET enabled documentation of lymphoma relapse in 41 cases at 6 months, in 30 cases at 12 months, in 26 cases at 18 months, in 10 cases at 24 months, and in 11 cases at more than 36 months. All 36 patients with inconclusive positive PET underwent biopsy; only 12 (33%) of 36 patients had a concomitant suggestion of positivity on CT. A lymphoma relapse was diagnosed in 24 (66%) of 36 patients., Conclusion: Our results confirm FDG-PET as a valid tool for follow-up of patients with HL and NHL. In patients with inconclusive positive results, histologic confirmation plays an important role in identifying true relapse.

Published
2009
Full Text
View/download PDF

27. Histological verification of positive positron emission tomography findings in the follow-up of patients with mediastinal lymphoma.

Author

Zinzani PL, Tani M, Trisolini R, Fanti S, Stefoni V, Alifano M, Castellucci P, Musuraca G, Dalpiaz G, Alinari L, Marchi E, Fina M, Pellegrini C, Farsad M, Cancellieri A, Busca A, Canini R, Pileri S, Baccarani M, and Boaron M

Subjects
Adolescent, Adult, Diagnostic Errors, Follow-Up Studies, Histology, Humans, Middle Aged, Retrospective Studies, Tomography, X-Ray Computed, Lymphoma, Non-Hodgkin diagnosis, Mediastinal Neoplasms diagnosis, Positron-Emission Tomography standards
Abstract

Background and Objectives: Follow-ups of patients with mediastinal lymphoma are not accurate if they rely on computed tomography (CT). Positron emission tomography (PET) has been suggested to be useful in several lymphoma settings, such as initial staging, evaluation of residual masses after therapy, and assessment of response early in the course of treatment. The aim of this retrospective study was to verify the reliability of positive PET scans of the mediastinum in following up patients with mediastinal lymphoma, using histological findings as a comparison., Design and Methods: From January 2002 to July 2005, 151 patients with mediastinal lymphoma (57 with Hodgkin's disease [HD] and 94 with aggressive non-Hodgkin's lymphoma [NHL]) were followed-up after the end of front-line treatment. Patients with a positive PET scan of the mediastinum underwent CT scanning and surgical biopsy., Results: In 30 (21 HD and 9 NHL) out of 151 patients (20%) a suspicion of lymphoma relapse was raised based on positive mediastinal PET scanning. Histology confirmed this suspicion in 17 (10 HD and 7 NHL) out of 30 patients (57%), whereas either benign (9 fibrosis, 3 sarcoid-like granulomatosis) or unrelated neoplastic conditions (1 thymoma) were demonstrated in the remaining 13 patients (43%). SUVmax was significantly higher among patients who had signs of relapse (17 true positive cases) than among those who stayed in remission (13 false positive cases), the median values being 5.95 (range, 3.5-26.9) and 2.90 (range, 1.4-3.3), respectively (p=0.01)., Interpretation and Conclusions: We suggest that a positive PET scan of the mediastinum of a patient being followed-up for a mediastinal lymphoma should not be considered sufficient for diagnostic purposes in view of its lack of discrimination. Histological confirmation can safely be carried out with various biopsy techniques, the choice of which should be made on the basis of the findings of the clinical and imaging studies of the individual case.

Published
2007
Full Text
View/download PDF

28. Phase II trial of temozolomide in patients with pretreated cutaneous T-cell lymphoma.

Author

Tani M, Fina M, Alinari L, Stefoni V, Baccarani M, and Zinzani PL

Subjects
Aged, Dacarbazine administration & dosage, Female, Humans, Lymphoma, T-Cell, Cutaneous epidemiology, Male, Middle Aged, Skin Neoplasms epidemiology, Temozolomide, Dacarbazine analogs & derivatives, Lymphoma, T-Cell, Cutaneous drug therapy, Skin Neoplasms drug therapy
Abstract

Between July 2003 and March 2004, nine patients with pretreated mycosis fungoides were enrolled into a phase II trial and were treated with temozolomide. The overall response rate was 33%. Further studies are needed to test the efficacy of temozolomide, alone or in combination in earlier stages of this disease.

Published
2005

29. Preliminary observations of a phase II study of reduced-dose alemtuzumab treatment in patients with pretreated T-cell lymphoma.

Author

Zinzani PL, Alinari L, Tani M, Fina M, Pileri S, and Baccarani M

Subjects
Aged, Alemtuzumab, Antibodies, Monoclonal therapeutic use, Antibodies, Monoclonal, Humanized, Antibodies, Neoplasm therapeutic use, Antineoplastic Agents therapeutic use, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Combined Modality Therapy, Cytomegalovirus physiology, Cytomegalovirus Infections etiology, Dose-Response Relationship, Drug, Drug Administration Schedule, Female, Humans, Male, Middle Aged, PUVA Therapy, Pilot Projects, Remission Induction, Virus Activation, Antibodies, Monoclonal administration & dosage, Antibodies, Neoplasm administration & dosage, Antineoplastic Agents administration & dosage, Lymphoma, T-Cell, Cutaneous drug therapy, Lymphoma, T-Cell, Peripheral drug therapy
Abstract

We assessed the impact of a reduced-dose (10 mg x 3/week for 4 weeks) schedule of alemtuzumab in 10 patients with pretreated cutaneous/peripheral T-cell lymphomas. The overall response rate was 60% (2 complete responses and 4 partial responses). In terms of infectious toxicity, cytomegalovirus reactivation occurred in 1 (10%) patient.

Published
2005

Catalog

Books, media, physical & digital resources
See catalog results